Holen Sie sich die Stockscreener-App
16.03
3.99%
0.6234
Schlusskurs vom Vortag:
$15.41
Offen:
$15.67
24-Stunden-Volumen:
621.07K
Relative Volume:
0.57
Marktkapitalisierung:
$977.58M
Einnahmen:
$13.73M
Nettoeinkommen (Verlust:
$-114.48M
KGV:
-8.7053
EPS:
-1.8418
Netto-Cashflow:
$-78.49M
1W Leistung:
+4.33%
1M Leistung:
+19.95%
6M Leistung:
+14.63%
1J Leistung:
-33.12%
1-Tages-Spanne:
$15.62
$16.25
1-Wochen-Bereich:
$14.61
$16.25
52-Wochen-Spanne:
$12.12
$35.34
Janux Therapeutics Inc Stock (JANX) Company Profile
Firmenname
Janux Therapeutics Inc
Sektor
Branche
Telefon
(858) 751-4493
Adresse
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
Compare JANX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
JANX
Janux Therapeutics Inc
|
16.03 | 947.70M | 13.73M | -114.48M | -78.49M | -1.8418 |
VRTX
Vertex Pharmaceuticals Inc
|
524.06 | 134.02B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.88 | 68.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
921.67 | 58.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
320.30 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
191.28 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-20 | Herabstufung | Barclays | Overweight → Underweight |
| 2026-04-15 | Herabstufung | UBS | Buy → Neutral |
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-09-17 | Eingeleitet | Barclays | Overweight |
| 2025-09-10 | Eingeleitet | Stifel | Buy |
| 2025-09-10 | Eingeleitet | Truist | Buy |
| 2025-09-04 | Eingeleitet | Guggenheim | Buy |
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2025-07-11 | Eingeleitet | Raymond James | Outperform |
| 2024-12-03 | Bestätigt | BTIG Research | Buy |
| 2024-12-03 | Bestätigt | H.C. Wainwright | Buy |
| 2024-11-22 | Eingeleitet | Leerink Partners | Outperform |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-09-06 | Eingeleitet | Stifel | Buy |
| 2024-05-30 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-03-21 | Eingeleitet | BTIG Research | Buy |
| 2024-03-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-04-06 | Eingeleitet | Wedbush | Outperform |
| 2022-11-14 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Janux Therapeutics Inc Aktie (JANX) Neueste Nachrichten
Price to sales forward of Janux Therapeutics, Inc. – NASDAQ:JANX - TradingView
JANX Stock Edges Up After Hours After Discontinuing Cancer Program In Favor Of Remaining Pipeline - Stocktwits
Is Janux Therapeutics, Inc. (JANX) Stock a Biotech Opportunity With Next-Generation Immunotherapy Potential? - Yahoo Finance
Janux Therapeutics, Inc.(NasdaqGM: JANX) dropped from Russell 2500 Growth Benchmark - marketscreener.com
Janux Therapeutics, Inc.(NasdaqGM: JANX) dropped from Russell 2000 Growth Benchmark - marketscreener.com
Janux Therapeutics, Inc.(NasdaqGM:JANX) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Janux Therapeutics, Inc.(NasdaqGM: JANX) dropped from Russell 3000 Growth Benchmark - marketscreener.com
5 Most Promising Cancer Stocks According to Wall Street Analysts - Insider Monkey
Discipline and Rules-Based Execution in JANX Response - Stock Traders Daily
JANX Forecast — Price Target — Prediction for 2027 - TradingView
Janux Therapeutics, Inc. Actuals & Estimates (NASDAQ:JANX) - TradingView
Janux Therapeutics, Inc. Actuals & Estimates (BX:JANX) - TradingView
Truist Financial Initiates Janux Therapeutics(JANX.US) With Buy Rating, Announces Target Price $26 - Moomoo
Form 8K Janux Therapeutics Inc For: 23 June By Investing.com - Investing.com India
Janux Therapeutics announces departure of chief medical officer By Investing.com - Investing.com Australia
Janux Therapeutics Announces Departure of Chief Medical Officer - TipRanks
Janux Therapeutics announces departure of chief medical officer - Investing.com
CMO exits Janux Therapeutics (NASDAQ: JANX) as company starts search - Stock Titan
JANX Q1 2026 Earnings: EPS Surprise Beats Estimates Amid Clinical ProgressAnalyst Coverage Count - dars.gov.et
Janux Therapeutics Inc (JANX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
JANX News | JANUX THERAPEUTICS INC (NASDAQ:JANX) - ChartMill
Janux Therapeutics Inc (JANX) Valuation: PE, PB & Fair Value Analysis - TradingKey
JANX SEC FilingsJanux Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Janux Therapeutics Inc (JANX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Janux Therapeutics Inc (JANX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Janux Therapeutics Inc (JANX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Janux Therapeutics Inc (JANX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Janux Therapeutics Inc (JANX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Janux Therapeutics Inc (JANX) Institutional Confidence - TradingKey
Top Cybin (HELP) Competitors 2026 - MarketBeat
Behavioral Patterns of JANX and Institutional Flows - Stock Traders Daily
Janux Therapeutics Reports Results of 2026 Annual Meeting - The Globe and Mail
Janux Therapeutics (JANX) details RSU and stock option grants to RA Capital–linked entities - Stock Titan
Janux Therapeutics (JANX) director reports RSU and option awards tied to RA Capital - Stock Titan
Janux Therapeutics (JANX) awards director RSUs and 15,500 options - Stock Titan
Janux Therapeutics (JANX) director awarded RSUs and stock options - Stock Titan
Director at Janux Therapeutics (JANX) gets new RSUs and stock options - Stock Titan
Shareholders back Janux Therapeutics (NASDAQ: JANX) board and pay - Stock Titan
Janux Therapeutics, Inc. (JANX) reports Q1 loss, lags revenue estimates - MSN
How much upside is left in Janux Therapeutics (JANX)? Wall Street analysts think 180.44% - MSN
Janux Therapeutics (JANX) Q1 2026 Earnings: Better-than-Expected Loss Reduction Highlights Pipeline ProgressNew Analyst Coverage - newsline.com
B of A Securities Maintains Janux Therapeutics (JANX) Buy Recommendation - MSN
JANX Technical Analysis & Stock Price Forecast - Intellectia AI
Finanzdaten der Janux Therapeutics Inc-Aktie (JANX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.18%
2.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):